ANAVEX LIFE SCIENCES CORP.: Item 5.02 filing

AVXL · Nasdaq · Biological Products, (No Diagnostic Substances) · Large accelerated filer<br>Smaller reporting company · NY · Form 8-K filed 2026-11-02

No executive or director changes reported in this Item 5.02 section.

Events in this filing

0 events: .

Names, stated reasons, successor status, compensation terms and the evidence quotes are shown to subscribers. See plans

Item 5.02 as filed

Item 5.02 no later than the date of the filing of this Current Report on Form 8-K with the Securities and Exchange
Commission, providing each of them with the opportunity to furnish the Company with a letter addressed to the Company stating whether
she or he agrees with the statements made by the Company herein and, if not, stating the respects in which he or she does not agree. The
Company will file any letter received by it from Dr. Ma, Mr. Patel and/or Dr. Senderowicz as an exhibit to an amendment to this Form 8-K
within two business days after receipt by the Company.

Source filing on EDGAR →